Figure 4.
Rebamipide inhibits PLD activity in gastric cancer cells. AGS and MKN-1 cells were labeled with [3H] myristate for 12 h, treated with 5 mM of rebamipide for the indicated times after which the PLD activity was measured. Each value represents the mean ± S.D. of three independent experiments. *P < 0.05 versus non-treatment.